New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
09:48 EDTPCYCPharmacyclics expects employees to sell shares during next open trading
Pharmacyclics said in its earnings release this morning that during the next open trading window which commences on November 7, it expects certain employees may exercise options they hold, and sell the shares immediately following the exercise. The company added that itís CEO and Chairman, Robert Duggan, does not anticipate selling any of his shares at the present time.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
10:00 EDTPCYCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Albemarle (ALB) upgraded to Buy from Hold at Topeka... American Capital Agency (AGNC) upgraded to Buy from Hold at Wunderlich... Bank of Hawaii (BOH) upgraded to Buy from Neutral at DA Davidson... Columbia Sportswear (COLM) upgraded to Hold from Sell at McAdams Wright... Costco (COST) upgraded to Conviction Buy from Neutral at Goldman... Ducommun (DCO) upgraded to Buy from Neutral at DA Davidson... Family Dollar (FDO) upgraded to Neutral from Underweight at Piper Jaffray... Ferrellgas Partners LP (FGP) upgraded to Neutral from Sell at Citigroup... Higher One (ONE) upgraded to Overweight from Underweight at Piper Jaffray... Landstar System (LSTR) upgraded to Buy from Hold at BB&T... MarkWest Energy (MWE) upgraded to Buy from Hold at Wunderlich... Matador (MTDR) upgraded to Outperform from Market Perform at BMO Capital... MicroStrategy (MSTR) upgraded at JMP Securities... Pharmacyclics (PCYC) upgraded to Outperform from Market Perform at Leerink... Provident Financial (PFS) upgraded at Sterne Agee... Sally Beauty (SBH) upgraded to Buy from Neutral at Citigroup... Tyson Foods (TSN) upgraded to Buy from Hold at Miller Tabak... WPX Energy (WPX) upgraded to Accumulate from Hold at Tudor Pickering... Zions Bancorp (ZION) upgraded at Bernstein.
07:46 EDTPCYCPharmacyclics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Pharmacyclics to Outperform citing increased expectations for Imbruvica in Chronic Lymphocytic Leukemia. After surveying 57 hematologists/oncologists, Leerink has an improved outlook for the drug. The firm raised its price target for shares to $142 from $102.
July 28, 2014
13:20 EDTPCYCPharmacyclics granted regular approval for Imbruvica
Subscribe for More Information
12:26 EDTPCYCPharmacyclics off lows, turns positive after FDA expands Imbruvica indication
Subscribe for More Information
12:24 EDTPCYCFDA expands approved use of Imbruvica for chronic lymphocytic leukemia
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica to treat patients with chronic lymphocytic leukemia who carry a deletion in chromosome 17, which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. The FDA is also approving new labeling to reflect that Imbruvicaís clinical benefit in treating CLL has been verified. Imbruvicaís new use is being approved more than two months ahead of the productís prescription drug user fee goal date of Oct. 7, the date the FDA was scheduled to complete review of the drug application. Imbruvica also received accelerated approval in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Clinical studies to verify and describe Imbruvicaís clinical benefit in mantle cell lymphoma are ongoing. Imbruvica is being jointly developed and commercialized in the United States by Pharmacyclics (PCYC) and Janssen Biotech (JNJ).
July 25, 2014
08:54 EDTPCYCEMA issues positive opinion, recommends approval of Imbruvica
Subscribe for More Information
July 23, 2014
14:32 EDTPCYCPharmacyclics estimates raised ahead of Q2 report at Goldman
Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data. The firm rates shares a Buy with a $162 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use